- Home
- APTO vs BIAF Comparison
APTO vs BIAF Comparison
Compare APTO & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APTO
- BIAF
- Stock Information
- Founded
- APTO 1986
- BIAF 2014
- Country
- APTO Canada
- BIAF United States
- Employees
- APTO N/A
- BIAF N/A
- Industry
- APTO Biotechnology: Biological Products (No Diagnostic Substances)
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- APTO Health Care
- BIAF Health Care
- Exchange
- APTO Nasdaq
- BIAF Nasdaq
- Market Cap
- APTO 13.2M
- BIAF 12.2M
- IPO Year
- APTO N/A
- BIAF 2022
- Fundamental
- Price
- APTO $0.16
- BIAF $0.83
- Analyst Decision
- APTO Strong Buy
- BIAF Strong Buy
- Analyst Count
- APTO 3
- BIAF 1
- Target Price
- APTO $4.33
- BIAF $6.00
- AVG Volume (30 Days)
- APTO 17.4M
- BIAF 76.9K
- Earning Date
- APTO 03-25-2025
- BIAF 03-31-2025
- Dividend Yield
- APTO N/A
- BIAF N/A
- EPS Growth
- APTO N/A
- BIAF N/A
- EPS
- APTO N/A
- BIAF N/A
- Revenue
- APTO N/A
- BIAF $9,367,785.00
- Revenue This Year
- APTO N/A
- BIAF $285.51
- Revenue Next Year
- APTO N/A
- BIAF $20.05
- P/E Ratio
- APTO N/A
- BIAF N/A
- Revenue Growth
- APTO N/A
- BIAF 2813.87
- 52 Week Low
- APTO $0.13
- BIAF $0.57
- 52 Week High
- APTO $1.94
- BIAF $3.62
- Technical
- Relative Strength Index (RSI)
- APTO 42.85
- BIAF 52.41
- Support Level
- APTO $0.13
- BIAF $0.75
- Resistance Level
- APTO $0.26
- BIAF $0.85
- Average True Range (ATR)
- APTO 0.02
- BIAF 0.06
- MACD
- APTO -0.00
- BIAF 0.01
- Stochastic Oscillator
- APTO 24.69
- BIAF 87.18
About APTO Aptose Biosciences Inc.
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.